The intestinal microvasculature as a therapeutic target in inflammatory bowel disease

Annals of the New York Academy of Sciences

Volumn 1072, Issue , 2006, Pages 78-97

  Hatoum, Ossama A ^a   Heidemann, Jan ^b   Binion, David G ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Alicaforsen; Angiogenesis; CCR9; Crohn's disease; Endothelial dysfunction; IBD; ICAM 1; MAdCAM 1; Microvessels; MLN02; Natalizumab; Ridogrel; Traficet EN; Ulcerative colitis

Indexed keywords

ALICAFORSEN; CHEMOKINE RECEPTOR CCR9; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; RIDOGREL;

ANGIOGENESIS; CONFERENCE PAPER; CROHN DISEASE; DRUG TARGETING; ENDOTHELIUM CELL; ENTERITIS; HUMAN; INTESTINE; INTESTINE MUCOSA; MICROVASCULATURE; PATHOPHYSIOLOGY; ULCERATIVE COLITIS;

EID: 33749016804     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1326.003     Document Type: Conference Paper

References (142)

1. PANES, J. & D.N. GRANGER. 1998. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 114: 1066-1190.
2. FIOCCHI, C. 1993. Cytokines and animal models: a combined path to inflammatory bowel disease pathogenesis. Gastroenterology 104: 1202-1205.
3. YOUNGMAN, K.R. et al. 1993. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 104: 749-758.
4. BINION, D.G. et al. 1997. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 112: 1895-1907.
5. BINION, D.G. et al. 1998. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 352: 1742-1746.
6. BINION, D.G. et al. 2000. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic. Biol. Med. 29: 881-888.
7. SALMI, M. et al. 1994. Aberrant binding of lamina propria lymphocytes to vascular endothelium in inflammatory bowel diseases. Gastroenterology 106: 596-605.
8. BURGIO, V.L. et al. 1995. Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease. Gastroenterology 109: 1029-1038.
9. BURNS, R.C. et al. 2001. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 121: 1428-1436.
10. RIVERA-NIEVES, J. et al. 2005. L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J. Immunol. 174: 2343-2352.
11. LEY, K. & G.S. KANSAS. 2004. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat. Rev. Immunol. 4: 325-335.
12. BACHMANN, C. et al. 2006. Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. Gastroenterology 130: 8-16.
13. TEDDER, T.F. et al. 1995. The selectins: vascular adhesion molecules. FASEB J. 9: 866-873.
14. TEDDER, T.F., D.A. STEEBER & P. PIZCUETA 1995. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J. Exp. Med. 181: 2259-2264.
15. PANES, J. et al. 1995. Regional differences in constitutive and induced ICAM-1 expression in vivo. Am. J. Physiol. 269(6 Pt 2): H1955-H1964.
16. PODOLSKY, D.K. et al. 1993. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J. Clin. Invest. 92: 372-380.
17. KOIZUMI, M. et al. 1992. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 103: 840-847.
18. SANS, M. et al. 1999. VCAM-I and ICAM-I mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 116: 874-883.
19. SORIANO, A. et al. 2000. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab. Invest. 80: 1541-1551.
20. CONNER, E.M. et al. 1997. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J. Pharmacol. Exp. Ther. 282: 1615-1622.
21. KAWACHI, S. et al. 2000. Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G734-G743.
22. VAN ASSCHE, G. & P. RUTGEERTS. 2002. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm. Bowel Dis. 8: 291-300.
23. DUSTIN, M.L. et al. 1986. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 137: 245-254.
24. ROTHLEIN, R. et al. 1986. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J. Immunol. 137: 1270-1274.
25. MARLIN, S.D. & T.A. SPRINGER. 1987. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51: 813-819.
26. DIAMOND, M.S. et al. 1990. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J. Cell. Biol. 111(6 Pt 2): 3129-3139.
27. KAVANAUGH, A.F. et al. 1994. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 37: 992-999.
28. BENNETT, C.F. et al. 1994. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J. Immunol. 152: 3530-3540.
29. NESTLE, F.O. et al. 1994. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J. Invest. Dermatol. 103: 569-575.
30. CHIANG, M.Y. et al. 1991. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266: 18162-18171.
31. HOKE, G.D. et al. 1991. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. 19: 5743-5748.
32. WICKSTROM, E. 1986. Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 13: 97-102.
33. YACYSHYN, B.R. et al. 1998. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114: 1133-1142.
34. SCHREIBER, S. et al. 2001. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120: 1339-1346.
35. VAN DEVENTER, S.J., J.A. TAMI & M.K. WEDEL. 2004. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 53: 1646-1651.
36. DIGNASS, A. et al. 1994. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J. Clin. Invest. 94: 376-383.
37. SANDBORN, W.J. & T.A. YEDNOCK. 2003. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am. J. Gastroenterol. 98: 2372-2382.
38. GHOSH, S. et al. 2003. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348: 24-32.
39. SANDBORN, W.J. et al. 2005. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353: 1912-1925.
40. FEAGAN, B.G. et al. 2005. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. 352: 2499-2507.
41. PAPADAKIS, K.A. & S.R. TARGAN. 2000. The role of chemokines and chemokine receptors in mucosal inflammation. Inflamm. Bowel Dis. 6: 303-313.
42. PAPADAKIS, K.A. 2004. Chemokines in inflammatory bowel disease. Curr. Allergy Asthma Rep. 4: 83-89.
43. PAPADAKIS, K.A. et al. 2003. CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J. Immunol. 171: 159-165.
44. PAPADAKIS, K.A. et al. 2001. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 121: 246-254.
45. PAPADAKIS, K.A. et al. 2000. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J. Immunol. 165: 5069-5076.
46. QIUPING, Z. et al. 2004. CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of living activation. Cancer Res. 64: 7579-7587.
47. ZHENG WEI, L.E., T. BAUMGART, W. RUBAS, et al. 2005. Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis. Gastroenterology 128: A-204-205.
48. FUNAYAMA, Y. et al. 1999. Remodeling of vascular wall in Crohn's disease. Dig. Dis. Sci. 44: 2319-2323.
49. WAKEFIELD, A.J. et al. 1991. Granulomatous vasculitis in Crohn's disease. Gastroenterology 100(5 Pt 1): 1279-1287.
50. HULTEN, L. et al. 1977. Regional intestinal blood flow in ulcerative colitis and Crohn's disease. Gastroenterology 72: 388-396.
51. ANGERSON, W.J. et al. 1993. Neoterminal ileal blood flow after ileocolonic resection for Crohn's disease. Gut 34: 1531-1534.
52. TATEISHI, S.,S. ARIMA & K. FUTAMI. 1997. Assessment of blood flow in the small intestine by laser Doppler flowmetry: comparison of healthy small intestine and small intestine in Crohn's disease. J. Gastroenterol. 32: 457-463.
53. BOGER, R.H. et al. 1998. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J. Am. Coll. Cardiol. 32: 1336-1344.
54. KERSTEIN, M.D. 1996. The non-healing leg ulcer: peripheral vascular disease, chronic venous insufficiency, and ischemic vasculitis. Ostomy Wound Manage. 42(10A Suppl): 19S-35S.
55. MONTORI, V.M. et al. 2002. Intermittent compression pump for nonhealing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000). Int. Angiol. 21: 360-366.
56. FLYNN, M.D. & J.E. TOOKE. 1992. Aetiology of diabetic foot ulceration: a role for the microcirculation? Diabet. Med. 9: 320-329.
57. VEVES, A. et al. 1998. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47: 457-463.
58. WHEATCROFT, S.B. et al. 2003. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet. Med. 20: 255-268.
59. HATOUM, O.A. et al. 2003. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 125: 58-69.
60. MORI, M. et al. 2005. Colonic blood flow responses in experimental colitis: time course and underlying mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G1024-G1029.
61. DVORAK, A.M., A.B. CONNELL & G.R. DICKERSIN. 1979. Crohn's disease: a scanning electron microscopic study. Hum. Pathol. 10: 165-177.
62. DVORAK, A.M. & G.R. DICKERSIN. 1979. Crohn's disease: electron microscopic studies. Pathol. Annu. 14(Pt 2): 259-306.
63. HARALDSEN, G. et al. 1995. Isolation and longterm culture of human intestinal microvascular endothelial cells. Gut 37: 225-234.
64. HARALDSEN, G. et al. 1996. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J. Immunol. 156: 2558-2565.
65. BINION, D.G. et al. 1998. iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am. J. Physiol. 275(3 Pt 1): G592-G603.
66. KUBES, P., M. SUZUKI & D.N. GRANGER. 1991. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA 88: 4651-4655.
67. KUBES, P. & D.M. MCCAFFERTY. 2000. Nitric oxide and intestinal inflammation. Am. J. Med. 109: 150-158.
68. HAYNES, W.G., A.P. DAVENPORT & D.J. WEBB. 1993. Endothelin: progress in pharmacology and physiology. Trends Pharmacol. Sci. 14: 225-228.
69. RUBANYI, G.M. & M.A. POLOKOFF. 1994. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46: 325-415.
70. MURCH, S.H. et al. 1992. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet 339: 381-385.
71. BECK, P.L. & D.K. PODOLSKY. 1999. Growth factors in inflammatory bowel disease. Inflamm. Bowel Dis. 5: 44-60.
72. HAMILTON, M.I. et al. 1995. Is proximal demarcation of ulcerative colitis determined by the territory of the inferior mesenteric artery? Lancet 345: 688-690.
73. WAKEFIELD, A.J. et al. 1989. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 2: 1057-1062.
74. NIELSEN, O.H. et al. 2000. Established and emerging biological activity markers of inflammatory bowel disease. Am. J. Gastroenterol 95: 359-367.
75. BREESE, E.J. et al. 1994. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466.
76. KLEMM, P. et al. 1995. Endothelin-1 mediates coronary vasoconstriction caused by exogenous and endogenous cytokines. J. Cardiovasc. Pharmacol. 26(Suppl 3): S419-S421.
77. WARNER, T.D. & P. KLEMM. 1996. What turns on the endothelins? Inflamm. Res. 45: 51-53.
78. RACHMILEWITZ, D. et al. 1992. Colonic endothelin-1 immunoreactivity in active ulcerative colitis. Lancet 339: 1062.
79. HAMBERG, M., J. SVENSSON & B. SAMUELSSON. 1975. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 72: 2994-2998.
80. CLAPP, N. et al. 1993. Inflammatory mediator changes in cotton-top tamarins (CTT) after SC-41930 anti-colitic therapy. Agents Actions 39(Spec. No. regular weight): C8-C10.
81. CLAPP, N. et al. 1993. Anti-colitic efficacy of SC-41930 in colitic cotton-top tamarins. Agents Actions 39(Spec. No. regular weight): C36-C38.
82. SHARON, P & W.F. STENSON. 1985. Metabolism of arachidonic acid in acetic acid colitis in rats: similarity to human inflammatory bowel disease. Gastroenterology 88(1 Pt 1): 55-63.
83. VILASECA, J. et al. 1990. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 98: 269-277.
84. KITSUKAWA, Y. et al. 1992. Effect of ingestion of eicosapentaenoic acid ethyl ester on carrageenan-induced colitis in guinea pigs. Gastroenterology 102: 1859-1866.
85. ZIFRONI, A. et al. 1983. Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut 24: 659-664.
86. RAMPTON, D.S. & C.E. COLLINS. 1993. Review article: thromboxanes in inflammatory bowel disease: pathogenic and therapeutic implications. Aliment. Pharmacol. Ther. 7: 357-367.
87. 14C]-arachidonic acid by human colonic mucosa. Gut 24: 1176-1182.
88. BOUGHTON-SMITH, N.K. & B.J. WHITTLE. 1983. Stimulation and inhibition of prostacyclin formation in the gastric mucosa and ileum in vitro by anti-inflammatory agents. Br. J. Pharmacol. 78: 173-180.
89. HAWKEY, C.J., N.K. BOUGHTON-SMITH & B.J. WHITTLE. 1985. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig. Dis. Sci. 30: 1161-1165.
90. HAWKEY, C.J. & D.S. RAMPTON. 1985. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology 89: 1162-1188.
91. HAWKEY, C.J. 1993. Gastroduodenal problems associated with non-steroidal, anti-inflammatory drugs (NSAIDs). Scand. J. Gastroenterol. 200(Suppl): 94-95.
92. LAURITSEN, K. et al. 1988. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut 29: 1316-1321.
93. LAURITSEN, K. & J. RASK-MADSEN. 1988. Prostaglandin analogues. Baillieres Clin. Gastroenterol. 2: 621-628.
94. LAURITSEN, K. et al. 1988. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut 29: 974-982.
95. LAURITSEN, K. et al. 1988. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology 95: 11-17.
96. KITCHEN, E.A., J.R. BOOT & W. DAWSON. 1978. Chemotactic activity of thromboxane B2, prostaglandins and their metabolites for polymorphonuclear leucocytes. Prostaglandins 16: 239-244.
97. GOLDMAN, G. et al. 1991. Thromboxane A2 induces leukotriene B4 synthesis that in turn mediates neutrophil diapedesis via CD 18 activation. Microvasc. Res. 41: 367-375.
98. WILES, M.E. et al. 1991. Thromboxane-induced neutrophil adhesion to pulmonary microvascular and aortic endothelium is regulated by CD 18. Inflammation 15: 181-199.
99. DOUKAS, J., H.B. HECHTMAN & D. SHEPRO. 1988. Endothelial-secreted arachidonic acid metabolites modulate polymorphonuclear leukocyte chemotaxis and diapedesis in vitro. Blood 71: 771-779.
100. USHIKUBI, F. et al. 1993. Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. J. Exp. Med. 178: 1825-1830.
101. KELLY, J.P., M.C. JOHNSON & C.W. PARKER. 1979. Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of the lipoxygenase pathway. J. Immunol. 122: 1563-1571.
102. ZIPSER, R.D. et al. 1985. Hypersensitive prostaglandin and thromboxane response to hormones in rabbit colitis. Am. J. Physiol. 249(4 Pt 1): G457-G463.
103. DHILLON, A.P. et al. 1992. Mucosal capillary thrombi in rectal biopsies. Histopathology 21: 127-133.
104. AUWERDA, J.J. et al. 2001. Ridogrel enemas in distal ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 13: 397-400.
105. TYTGAT, G.N. et al. 2002. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment. Pharmacol. Ther. 16: 87-99.
106. RISAU, W. 1997. Mechanisms of angiogenesis. Nature 386: 671-674.
107. FOLKMAN, J. 1985. Tumor angiogenesis. Adv. Cancer Res. 43: 175-203.
108. WALSH, D.A. 1999. Angiogenesis and arthritis. Rheumatology (Oxford) 38: 103-112.
109. FOLKMAN, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1: 27-31.
110. HANAHAN, D. & J. FOLKMAN. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
111. POLVERINI, P.J. 1997. Role of the macrophage in angiogenesis-dependent diseases. EXS 79: 11-28.
112. CARMELIET, P. et al. 1999. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98: 147-157.
113. CARMELIET, P. et al. 1999. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5: 495-502.
114. CARMELIET, P. & D. COLLEN. 1999. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr. Top. Microbiol. Immunol. 237: 133-158.
115. FERRARA, N. & K. ALITALO. 1999. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5: 1359-1364.
116. Qu, Z. et al. 1995. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab. Invest. 73: 339-346.
117. Qu, Z. et al. 1995. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am. J. Pathol. 147: 564-573.
118. WALSH, D.A. et al. 1998. Focally regulated endothelial proliferation and cell death in human synovium. Am. J. Pathol. 152: 691-702.
119. WALSH, D.A. & P.I. MAPP. 1998. Joint physiology and synovial cell proliferation. Br. J. Rheumatol. 37: 1032-1033.
120. WALSH, D.A., H.A. RODWAY & A. CLAXSON. 1998. Vascular turnover during carrageenan synovitis in the rat. Lab. Invest. 78: 1513-1521.
121. JONES, A.L. et al. 2005. Histidine-richglycoprotein specifically binds to necrotic cells via its amino-terminal domain and facilitates necrotic cell phagocytosis. J. Biol. Chem. 280: 35733-35741.
122. HATTON, M.W. et al. 2004. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: effluxing fibrin(ogen) fragments contain antiangiogenic activity. J. Lab. Clin. Med. 143: 241-254.
123. DALY, M.E. et al. 2003. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J. Natl. Cancer Inst. 95: 1660-1073.
124. SCAPINI, P. et al. 2002. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J. Immunol. 168: 5798-5804.
125. COLLIN-OSDOBY, P. et al. 2002. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J. Bone Miner. Res. 17: 1859-1871.
126. OGAWA, H. et al. 2005. Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. Am. J. Physiol. Cell. Physiol. 288: C272-C281.
127. OKADA, F. 2002. Inflammation and free radicals in tumor development and progression. Redox. Rep. 7: 357-368.
128. CRIVELLATO, E. & D. RIBATTI. 2005. Involvement of mast cells in angiogenesis and chronic inflammation. Curr. Drug Targets Inflamm. Allergy 4: 9-11.
129. MILKIEWICZ, M. et al. 2001. Association between shear stress, angiogenesis, and VEGF in skeletal muscles in vivo. Microcirculation 8: 229-241.
130. CULLEN, J.P. et al. 2002. Pulsatile flow-induced angiogenesis: role of G(i) subunits. Arterioscler. Thromb. Vasc. Biol. 22: 1610-1616.
131. SCHAPER, W. & D. SCHOLZ. 2003. Factors regulating arteriogenesis. Arterioscler. Thromb. Vasc. Biol. 23: 1143-1151.
132. CONTRAN, R.S. 1994. Robbins Pathologic Basis of Disease. 5th Ed. W. B. Saunders. Philadelphia.
133. SAITO, S. et al. 2003. Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease. J. Gastroenterol. 38: 229-237.
134. KANAZAWA, S. et al. 2001. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am. J. Gastroenterol. 96: 822-828.
135. ROBOTTI, D. et al. 2004. Activity of Crohn disease: value of Color-Power-Doppler and contrast-enhanced ultrasonography. Abdom. Imaging 29: 648-652.
136. DI SABATINO, A., E. ARMELLINI & G.R. CORAZZA. 2004. Doppler sonography in the diagnosis of inflammatory bowel disease. Dig. Dis. 22: 63-66.
137. DANESE, S.S.M., D. SPENCER, I. BECK, et al. 2005. Starving the inflamed gut: angiogenesis blocked as a novel therapeutic approach to experimental colitis. Gastroenterology 128: A-40.
138. STUPACK, D.G., C.M. STORGARD & D.A. CHERESH. 1999. A role for angiogenesis in rheumatoid arthritis. Braz. J. Med. Biol. Res. 32: 573-581.
139. JACKSON, J.R. et al. 1997. Modulation of angiogenesis in a model of chronic inflammation. Inflamm. Res. 46(Suppl 2:) S129-S130.
140. HIRATA, S. et al. 1989. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 32: 1065-1073.
141. ROCCARO, A.M. et al. 2005. Antiangiogenesis for rheumatoid arthritis. Curr. Drug Targets Inflamm. Allergy 4: 27-30.
142. MATSUNO, H. et al. 2002. Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. J. Rheumatol. 29: 890-895.